The UK government announced an inquiry by the House of Lords Science and Technology Committee to examine how artificial intelligence can optimize clinical trials and bridge gaps between early research, trials, and NHS implementation. The probe will consider barriers such as procurement processes, clinical pathways, and the role of regulators and professional bodies. The inquiry is part of the Labour government’s “AI for science” strategy, which includes an aim to use AI to develop “trial-ready drugs” within 100 days by 2030. The committee said it wants to establish where patients might benefit from near-term developments in genomics, AI, and personalized medicine. The government points to earlier steps that reportedly cut UK clinical trial approval times to about 41 days using digital reforms at the Medicines and Healthcare products Regulatory Agency. It also cited work on the IXI Brain Atlas project, which supports more than 40 clinical trials into neurodegenerative diseases by analyzing brain scans. For biotech, the focus is on execution: AI adoption isn’t just a research tool, but a potential lever for trial readiness, regulatory acceleration, and downstream delivery across the NHS.